Toxoplasmosis Treatment Market Expected to Reach $1.1 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Toxoplasmosis Treatment Market," The toxoplasmosis treatment market size was valued at $683.11 million in 2021, and is estimated to reach $1,093.88 million by 2031, growing at a CAGR of 4.8% from 2022 to 2031.

The toxoplasmosis disease is a transmitted disease, which is transferred from animal to human, or mother to child during pregnancy, and can spread through cat feces or contaminated food. It is caused by single celled parasite known as Toxoplasma gondii, which is a protozoan parasite that infects most species of warm-blooded animals, including humans and causes the disease toxoplasmosis.

Toxoplasmosis treatment includes inhibitors of dihydrofolate reductase (DHFR) (pyrimethamine and trimethoprim), and dihydropteroate synthetase (sulfonamides, such as sulfadiazine, sulfamethoxazole, and sulfadoxine), which block the folic acid synthesis. This treatment is used in patients who are suffering from parasitic infection (toxoplasmosis disease) and mostly it is used in pregnant women and infants.

Toxoplasmosis treatment market trends which drive growth of market include rise in government awareness programs for toxoplasmosis and continuous increase in unhygienic environment in popular countries. In addition, major players are investing in development and commercialization of toxoplasmosis products to decrease incidences of toxoplasmosis disease that fuel the growth of market.

Moreover, Increase in number of chemotherapy procedures can lead to rise in number of toxoplasmosis infection, thereby boosting the growth toxoplasmosis treatment market forecast. Furthermore, toxoplasma IgG immunoglobulin level rises by 4 times higher in cancer patients which causes toxoplasmosis. Thus, rise in incidences of cancer disease increases the demand for toxoplasmosis treatment and further boosts the market growth. 

Depending on type, the market is bifurcated into acquired toxoplasmosis and congenital toxoplasmosis. The acquired toxoplasmosis segment exhibited largest toxoplasmosis treatment market share in 2021, owing to rise in prevalence of acquired toxoplasmosis caused due to accidental consumption of oocysts after coming into contact with or consuming something that has contact with toxoplasma-infected cat feces.

On the basis of route of administration, the market is segmented into oral and parenteral. The oral segment exhibited highest growth in 2021 and is expected to remain dominant during the forecast period, owing to advantages associated with oral route such as more pre-determined doses, convenience, patient self-administration, and easy to administer. For instance, Dr. Reddy's Laboratories Ltd. have the product Pyrimethamine Tablets USP, 25 mg, (Daraprim) which is available in oral form.

On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The hospital pharmacies segment dominated the toxoplasmosis treatment market in 2021, owing to factors such as large number of patient visits to the hospital pharmacies as they offer the precise drug according to status of disease of patient and easy accessibility of the facilities.

Moreover, the online providers segment is projected to register a CAGR of 6.3% during the forecast period, owing to rise in digitalization around the globe. In addition, availability of a variety of toxoplasmosis drugs such as Daraprim on e-commerce platforms is more than pharmacies or retail stores, which helps patients buy products at ease propel the segment growth.

Region wise, North America had the highest toxoplasmosis treatment market share in 2021. This was attributed to rise in cases of parasitic infection cause the toxoplasmosis disease. In addition, strong presence of key players such as Alvogen, Oakrum Pharma, and Vyera Pharmaceuticals LLC that offers the toxoplasmosis treatment further boost the market growth in the region.

However, Asia-Pacific is expected to witness highest growth during the forecast period, owing to rise in prevalence of toxoplasmosis infection. In addition, rise in awareness programs for toxoplasmosis disease further boosts the toxoplasmosis treatment market size growth in this region.

Key findings of the study
• By type, the acquired toxoplasmosis segment was highest contributor to the toxoplasmosis treatment industry in 2021. However, the congenital toxoplasmosis segment is anticipated to grow at the highest CAGR during the forecast period.
• On the basis of route of administration, the oral segment was dominated the toxoplasmosis treatment industry in 2021.
• By distribution channel, the hospital pharmacies segment dominated the market in 2021. However, online providers segment is anticipated to grow at the highest CAGR during the forecast period.
• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the toxoplasmosis treatment market analysis.